Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 27 Feb 2018
At a glance
- Drugs Semaglutide (Primary) ; Liraglutide
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms PIONEER 9
- Sponsors Novo Nordisk
- 20 Dec 2017 Planned End Date changed from 6 Sep 2018 to 20 Aug 2018.
- 20 Dec 2017 Planned primary completion date changed from 2 Aug 2018 to 26 Jan 2018.
- 21 Nov 2017 According to a Novo Nordisk media release, the trial is expected to be completed in 2018.